Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the EURETINA Innovation Spotlight being held as part of the 25^th EURETINA Congress on September 3, 2025 in Le Palais des Congrès, Paris.

Read more at globenewswire.com